Drugs / OKI-219
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06239467 | Feb 2024 → Dec 2026 expected | breast cancer | OnKure, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OKI-219 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06239467 ↗ |
| Action | Inhibit | “PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy” NCT06239467 ↗ |
| Route | Oral | “Oral twice daily” NCT06239467 ↗ |